What were the effects of Candesartan on mortality and morbidity for patients with chronic heart failure?
The CHARM-Overall Programme study reported that Candesartan reduced mortality and morbidity in patients with chronic heart failure. It was also reported to reduce mortality in patients with myocardial infarction who also had left ventricular dysfunction or heart failure. The Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANCEND) found that telmisartan reduced the risk of cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors. Additionally, the ONTARGET study found that telmisartan, in combination with ramipril, was more effective than either drug alone in reducing the risk of vascular events in high risk patients. Finally, the Systematic Review of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers for Treating Essential Hypertension concluded that both types of drugs were effective in treating essential hypertension.  